Basel, 30 July 2018 Invitation to Roche’s Virtual Late Stage Pipeline Event 2018 We are pleased to invite investors and analysts to participate in a live video webcast and conference call on Thursday, 13 September 2018, highlighting development and commercial opportunities within our late stage portfolio. We would like to invite all interested parties to... Read more
Basel, 27 July 2018 Reminder: Invitation to Roche’s Virtual Pipeline Event: Phase 2 LADDER results of the Port Delivery System (PDS) with Lucentis to be presented at the 2018 ASRS annual meeting We are pleased to invite investors and analysts to participate in a live audio webcast and conference call on Thursday, 2 August 2018,... Read more
Basel, 26 July 2018 Roche presents positive phase II results for the first-ever eye implant demonstrating sustained delivery of a biologic medicine to treat people with neovascular age-related macular degeneration Roche’s investigational Port Delivery System with ranibizumab (PDS) is intended to reduce the burden of frequent eye injections for people with neovascular age-related macular degeneration... Read more
Basel, 24 July 2018 Roche Analyst Event on Diagnostics Division at AACC 2018: Tuesday, 31st July, 6:00pm CDT Roche has held an analyst event on Tuesday, 31st July 2018 to discuss Roche’s Diagnostics Division, in conjunction with the American Association for Clinical Chemistry (AACC) Annual Meeting and Clinical Lab Exposition in Chicago, Illinois (July 30-August... Read more
Basel, 23 July 2018 Roche receives CE Mark for its Accu-Chek Solo micropump system The Accu-Chek Solo micropump is a small, tube-free insulin delivery system that offers users the choice to bolus directly from the pump or from the fully-functional handheld as well as to detach and re-attach the pump without wasting insulin. The Accu-Chek... Read more
Basel, 23 July 2018 Roche receives CE Mark for its Accu-Chek Solo micropump system The Accu-Chek Solo micropump is a small, tube-free insulin delivery system that offers users the choice to bolus directly from the pump or from the fully-functional handheld as well as to detach and re-attach the pump without wasting insulin. The Accu-Chek... Read more
Basel, 20 July 2018 Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on amyloid beta oligomer levels in CSF Two year open-label extension updates for investigational gantenerumab will include data on... Read more
Basel, 20 July 2018 Roche to present new data demonstrating the breadth and depth of its Alzheimer’s programme at the upcoming Alzheimer’s Association International Conference Late-breaking Phase II exploratory analysis of investigational crenezumab to show impact on amyloid beta oligomer levels in CSF Two year open-label extension updates for investigational gantenerumab will include data on... Read more
Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more
Basel, 20 July 2018 FDA grants Breakthrough Device Designation for Roche’s Elecsys cerebrospinal fluid (CSF) assays to support the improved diagnosis of Alzheimer’s disease Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Elecsys® ß-Amyloid (1-42) CSF and Elecsys® Phospho-Tau (181P) CSF.... Read more